Delivery Order SPE2DB22D1041-SPE2DB25FUAP4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,096.94 to AmerisourceBergen Drug Corp for Loteprednol Etabonate 0.5% ophthalmic drops (5 mL) on August 18, 2025, with completion scheduled for August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Loteprednol Etabonate 0.2% ophthalmic drops in 5 milliliter units, with a ceiling value of $1,650.30 and an ultimate completion date of October 22, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government and will be performed at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,886.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Loteprednol Etabonate 0.2% ophthalmic drops in 5ML quantities. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by July 22, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,842.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Loteprednol Etabonate 0.2% ophthalmic drops in 5 mL quantities. The contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is non-competitive and scheduled for completion by August 1, 2025. Performance will be fulfilled...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The $1,240.45 firm fixed-price contract is for the delivery of Loteprednol Etabonate 0.5% ophthalmic drops. The order has a completion date of June 23, 2025 and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Loteprednol Etabonate 0.2% ophthalmic drops in a 5 mL unit, with a ceiling value of $1,267.04. This competitive award utilizes a firm fixed price structure and is classified as a child contract under a larger vehicle. The performance location is identified as Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. No set-aside designation was applied...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,273.07 firm fixed-price delivery order is for the supply of loteprednol etabonate 0.5% eye drops, a medication used for the treatment of various eye conditions. The contract has an ultimate completion date of May 24, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Loteprednol Etabonate 0.2% ophthalmic drops (5ml) under a firm fixed price contract valued at $1,743.19. This non-competitive delivery order, issued on December 19, 2025, represents a small pharmaceutical procurement for military healthcare logistics. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania, with completion expected by December 22, 2025. This...
- This delivery order, valued at $2,630.16, was awarded on August 19, 2025, to AmerisourceBergen Drug Corp for the supply of Loteprednol Etabonate 0.5% ophthalmic suspension. The contract is a firm fixed-price delivery order issued under the Defense Logistics Agency's Medical Supply Chain program, with performance to be completed by August 19, 2025, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award was made on a competitive, non-set-aside basis, consistent with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,640.84 firm fixed-price delivery order is for the supply of Loteprednol Etabonate 0.5% Eye Drops, 5 ml, with a completion date of July 25, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUAP4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of Loteprednol Etabonate 0.5% ophthalmic drops in 5 mL quantities, with a ceiling value of $2,508.45. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The contract calls for completion by May 7, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive pharmaceutical supply vehicle running through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a wide range of medical products to support military healthcare systems, Defense Health Agency operations, and other government healthcare programs globally. The company's extensive portfolio includes specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains, positioning it as a key provider within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 5/6/25 |